BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Short Interest Down 80.0% in March

BriaCell Therapeutics Corp. (NASDAQ:BCTXW) saw a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 300 shares, a decline of 80.0% from the March 15th total of 1,500 shares. Based on an average daily volume of 56,400 shares, the short-interest ratio is currently 0.0 days.

BriaCell Therapeutics Stock Performance

Shares of NASDAQ:BCTXW traded down $0.02 on Monday, reaching $0.08. 924 shares of the company were exchanged, compared to its average volume of 102,760. BriaCell Therapeutics has a 1-year low of $0.03 and a 1-year high of $1.30. The company has a 50-day moving average of $0.10 and a 200-day moving average of $0.23.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.